CZChengxi Zang

Chengxi Zang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chengxi Zang has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world effectiveness of Paxlovid in protecting Long COVID for outpatient adult patients: A target trial emulation study from the RECOVER Initiative

    by Chengxi Zang, Haoyang Li, Dhruv Khullar, Yongkang Zhang, Stephenson Strobel, Yong Chen, Marc A. Sala, Payal Bharat Patel, Alejandro P. Comellas, Andrew Wylam, et al.

    Paxlovid (nirmatrelvir/ritonavir) has been approved for use in patients who are at high risk for severe acute COVID-19 illness. Evidence regarding whether acute use of Paxlovid protects against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or Long COVID, is mixed in high-risk patients and lacking in low-risk patients. With a target trial emulation framework, we evaluated the association of Paxlovid treatment within 5 days of SARS-CoV-2 infection with incident Long COVID and hospitalization or death from any cause in the post-acute period (30–180 days after infection) using electronic health records from the Patient-Centered Clinical Research Networks (PCORnet) RECOVER repository. The study population included 497,499 SARS-CoV-2 positive patients between March 1, 2022, to February 28, 2023. For those who had at least 1 risk factor for severe COVID-19 illness, 159,659 were treated with at least one dose of Paxlovid within 5 days since infection and 272,048 were not treated with Paxlovid or other COVID-19 treatments during the acute infection period. Compared with the non-treated group, Paxlovid treatment was associated with reduced risk of Long COVID with a Hazard Ratio (HR) of 0.88 (95% CI, 0.87 to 0.89) and absolute risk reduction of 2.99 events per 100 persons (95% CI, 2.65 to 3.32). For those without documented risk factors, the associations (HR, 1.03, 95% CI 0.95 to 1.11; risk increase 0.80 events per 100 persons, 95% CI -0.84 to 2.45) were inconclusive. High-risk, nonhospitalized adult patients with COVID-19 who were treated with Paxlovid within 5 days of SARS-CoV-2 infection had a lower risk of Long COVID and all-cause hospitalization or death in the post-acute period. However, Long COVID risk reduction with Paxlovid was not observed in low-risk patients.

  • Open Access

    Federated causal inference for effect estimation in healthcare: methods, challenges, and applications

    by Haoyang Li, Zheqi Lyu, Meihan Wei, Simai Cheng, Wenhan Zheng, Fuying Ding, Jie Xu, Kyra Gan, Max Sunog, Colin Magdamo, et al.


  • Open Access

    Agentic AIGC: A Survey of Visual Generation Agents

    by Zihan Xing, Jin Wang, Rong Xia, Keming Ye, Zhan Qu, Biao Yi, Tianqi Liu, Junhao Chen, Jie Yang, Zhibo Zhu, et al.

    Visual generation is becoming a general component of AI infrastructure, supporting content creation across design, entertainment, education, science, and industry. Generative and multimodal models have substantially improved single-pass synthesis. At the same time, multi-step visual creation requires spatial precision, identity persistence, temporal coherence, editable structure, factual fidelity, and physical plausibility throughout the creation process. Errors in intermediate artifacts can propagate across subsequent steps, making creation control a central requirement. Model scaling, prompt refinement, additional conditioning, and repeated sampling improve individual outputs; coordinating these capabilities across a task requires runtime evidence to influence subsequent creation decisions. Within AI-generated content (AIGC), we use Agentic AIGC to describe goal-driven content creation organized through a multi-step control loop. This survey focuses on visual generation agents: systems that use runtime evidence from evolving visual artifacts, task environments, and interaction histories to change later creation-relevant action selection or parameterization, including generation, editing, verification, recovery, replanning, and stopping. The defining behavioral property is therefore an observation--action dependency: runtime observations change later action selection. Whether those decisions improve task or constraint outcomes is evaluated separately with matched tools and resource budgets. We organize this emerging field around the control mechanisms and behavioral evidence that connect generative capabilities to autonomous visual creation. Specifically, we formalize this boundary and characterize autonomy through five cumulative levels (L1--L5). A six-component analytical framework (goal understanding, specification, and planning; memory; tool; perception; action; and cross-task self-improvement) structures a cross-domain comparison spanning image, video, 3D/CAD, scientific visualization, structured documents, UI/Web, and related visual-creation domains. Building on this comparison, we analyze training from trajectory supervision and policy initialization through reinforcement learning from multimodal and executable feedback to experience reuse with skill abstraction and transfer. We organize evaluation into four complementary levels: artifact quality, goal and constraint satisfaction, trajectory and decision quality, and system and human-centered evaluation. This synthesis distinguishes behavioral evidence from evidence that feedback improves a creation outcome. Finally, we identify research directions in the scope of visual agency, reliable long-horizon control, cross-task improvement, and evaluation.

  • Open Access

    Empowering clinical trial design with agentic intelligence and real-world data

    by Haoyang Li, Weishen Pan, Suraj Rajendran, Chengxi Zang, Fei Wang

    Clinical trial design (CTD) is a time-consuming process that requires substantial domain expertise. Large-scale real-world data (RWD), such as electronic health records (EHR), encodes practice-based evidence that is of tremendous value to CTD. In recent years, many machine learning methods have been developed to extract such real-world evidence (RWE) from the RWD to inform CTD, but they still need to be communicated with the domain experts extensively in an iterative manner to be further refined and ultimately useful. In this paper, we introduce EmulatRx, an agentic framework that derives RWE for helping with CTD. Through the iterative conversation and analysis across agents with different roles, EmulatRx can autonomously refine trial protocols and finally generate a robust report containing insights that inform better CTD. We applied EmulatRx on the CTD process for both acute diseases (e.g., septic shock, acute heart failure, acute pulmonary edema, and acute kidney injury) using the MIMIC-IV data and chronic diseases (e.g., Alzheimer's disease and Parkinson's disease) using the INSIGHT Network across five New York City health systems. The results demonstrate EmulatRx's capabilities in facilitating and accelerating the CTD process.


  • Open Access

    SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative

    by Ting Zhou, Bingyu Zhang, Yiwen Lu, Jiajie Chen, Chengxi Zang, Haoyang Li, Josephine Elia, Raghuram Prasad, Jonathan Arnold, Sean N. Avedissian, et al.


  • Open Access

    Multicenter target trial emulation to evaluate corticosteroids for sepsis stratified by predicted organ dysfunction trajectory

    by Suraj Rajendran, Zhenxing Xu, Weishen Pan, Chengxi Zang, Ilias Siempos, Lisa Torres, Jie Xu, Jiang Bian, Edward J. Schenck, Fei Wang

    Corticosteroids decrease the duration of organ dysfunction in sepsis and a range of overlapping and complementary infectious critical illnesses, including septic shock, pneumonia and the acute respiratory distress syndrome (ARDS). The risk and benefit of corticosteroids are not fully defined using the construct of organ dysfunction duration. This retrospective multicenter, proof-of-concept study aimed to evaluate the association between usage of corticosteroids and mortality of patients with sepsis, pneumonia and ARDS by emulating a target trial framework stratified by predicted organ dysfunction trajectory. The study employed a two staged machine learning (ML) methodology to first subphenotype based on organ dysfunction trajectory then predict this defined trajectory. Once patients were classified by predicted trajectory we conducted a target trial emulation. Our analysis revealed that the association between corticosteroid use and 28-day mortality varied by predicted trajectory and between cohorts.Our findings suggest that matching treatment strategies to empirically observed pathobiology may offer a more nuanced understanding of corticosteroid utility.


  • Open Access

    Federated Causal Inference in Healthcare: Methods, Challenges, and Applications

    by Haoyang Li, Jie Xu, Kyra Gan, Fei Wang, Chengxi Zang

    Federated causal inference enables multi-site treatment effect estimation without sharing individual-level data, offering a privacy-preserving solution for real-world evidence generation. However, data heterogeneity across sites, manifested in differences in covariate, treatment, and outcome, poses significant challenges for unbiased and efficient estimation. In this paper, we present a comprehensive review and theoretical analysis of federated causal effect estimation across both binary/continuous and time-to-event outcomes. We classify existing methods into weight-based strategies and optimization-based frameworks and further discuss extensions including personalized models, peer-to-peer communication, and model decomposition. For time-to-event outcomes, we examine federated Cox and Aalen-Johansen models, deriving asymptotic bias and variance under heterogeneity. Our analysis reveals that FedProx-style regularization achieves near-optimal bias-variance trade-offs compared to naive averaging and meta-analysis. We review related software tools and conclude by outlining opportunities, challenges, and future directions for scalable, fair, and trustworthy federated causal inference in distributed healthcare systems.


  • Open Access

    Long COVID after SARS-CoV-2 during pregnancy in the United States

    by Chengxi Zang, Daniel Guth, Ann M. Bruno, Zhenxing Xu, Haoyang Li, Nariman Ammar, Robert Chew, Nick Guthe, Emily Hadley, Rainu Kaushal, et al.

    Pregnancy alters immune responses and clinical manifestations of COVID-19, but its impact on Long COVID remains uncertain. This study investigated Long COVID risk in individuals with SARS-CoV-2 infection during pregnancy compared to reproductive-age females infected outside of pregnancy. A retrospective analysis of two U.S. databases, the National Patient-Centered Clinical Research Network (PCORnet) and the National COVID Cohort Collaborative (N3C), identified 29,975 pregnant individuals (aged 18–50) with SARS-CoV-2 infection in pregnancy from PCORnet and 42,176 from N3C between March 2020 and June 2023. At 180 days after infection, estimated Long COVID risks for those infected during pregnancy were 16.47 per 100 persons (95% CI, 16.00–16.95) in PCORnet using the PCORnet computational phenotype (CP) model and 4.37 per 100 persons (95% CI, 4.18–4.57) in N3C using the N3C CP model. Compared to matched non-pregnant individuals, the adjusted hazard ratios for Long COVID were 0.86 (95% CI, 0.83–0.90) in PCORnet and 0.70 (95% CI, 0.66–0.74) in N3C. The observed risk factors for Long COVID included Black race/ethnicity, advanced maternal age, first- and second-trimester infection, obesity, and comorbid conditions. While the findings suggest a high incidence of Long COVID among pregnant individuals, their risk was lower than that of matched non-pregnant females.


  • Open Access

    Single‐microglia transcriptomic transition network‐based prediction and real‐world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease

    by Jielin Xu, Wenqiang Song, Zhenxing Xu, Michael M. Danziger, Ehud Karavani, Chengxi Zang, Xin Chen, Yichen Li, Isabela M Rivera Paz, Dhruv Gohel, et al.

    INTRODUCTION: High microglial heterogeneities hinder the development of microglia‐targeted treatment for Alzheimer's disease (AD). METHODS: We integrated 0.7 million single‐nuclei RNA‐sequencing transcriptomes from human brains using a variational autoencoder. We predicted AD‐relevant microglial subtype‐specific transition networks for disease‐associated microglia (DAM), tau microglia, and neuroinflammation‐like microglia (NIM). We prioritized drugs by specifically targeting microglia‐specific transition networks and validated drugs using two independent real‐world patient databases. RESULTS: We identified putative AD molecular drivers (e.g., SYK , CTSB , and INPP5D ) in transition networks of DAM and NIM. Via specifically targeting NIM, we identified that usage of ketorolac was associated with reduced AD incidence in both MarketScan (hazard ratio [HR] = 0.89) and INSIGHT (HR = 0.83) Clinical Research Network databases, mechanistically supported by ketorolac‐treated transcriptomic data from AD patient induced pluripotent stem cell–derived microglia. DISCUSSION: This study offers insights into the pathobiology of AD‐relevant microglial subtypes and identifies ketorolac as a potential anti‐inflammatory treatment for AD. Highlights: An integrative analysis of ≈ 0.7 million single‐nuclei RNA‐sequencing transcriptomes from human brains identified Alzheimer's disease (AD)–relevant microglia subtypes. Network‐based analysis identified putative molecular drivers (e.g., SYK, CTSB, INPP5D ) of transition networks between disease‐associated microglia (DAM) and neuroinflammation‐like microglia (NIM). Via network‐based prediction and population‐based validation, we identified that usage of ketorolac (a US Food and Drug Administration–approved anti‐inflammatory medicine) was associated with reduced AD incidence in two independent patient databases. Mechanistic observation showed that ketorolac treatment downregulated the Type‐I interferon signaling in patient induced pluripotent stem cell–derived microglia, mechanistically supporting its protective effects in real‐world patient databases.